Navigation Links
Cardium Announces Temporary Adjournment of Annual Meeting To Be Reconvened On July 2, 2013
Date:6/21/2013

in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that certain elements of the preferred stock financing or other matters submitted for approval by stockholders will be approved by stockholders; that the Company will satisfy the requirements of its compliance plan and will otherwise continue to satisfy the listing requirements of its exchange or that its shares can continue to be listed on a national exchange; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that our To Go Brands business can be successfully integrated and expanded; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that the preferred stock offering can be completed as proposed or that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements t
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Reports On NYSE MKT Noncompliance Notice And Compliance Plan
2. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
3. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
4. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
5. Cardium to Present at Upcoming Investor Conferences
6. China Green Agriculture Inc. Announces Ministry of Agriculture Engaged Gufeng as Corporate Participant in the Ministrys Fertilizer Promotion Program
7. Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System
8. Techne Corporation Announces Acquisition Agreement
9. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
10. Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions
11. Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Shimadzu Scientific Instruments ... multipurpose UV-visible spectrophotometer. Offering wavelength scanning from 190 ... ideal for applications in a variety of industries, ... The user-friendly UV-1280 enables intuitive operation, while the ...
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2
... 27 Soligenix, Inc., (Soligenix or the Company) (OTC ... a late-stage biotechnology company, announced today that its Chief ... highlighting recent developments at the BIO Investor Forum. , ... 2009 at 1:00 PM PDT at The Palace Hotel ...
... ... , ... October 27, 2009 -- Global food security, which is increasingly being recognized as a ... and private partnerships, William S. Niebur , vice president – DuPont Crop Genetics ...
... Cynosure, Inc. (Nasdaq: CYNO ), a leading developer and ... today announced financial results for the three and nine months ... Results , Revenues for the three months ended September ... the same period of 2008 and $20.8 million for the ...
Cached Biology Technology:Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Cynosure Reports Third Quarter 2009 Financial Results 2Cynosure Reports Third Quarter 2009 Financial Results 3Cynosure Reports Third Quarter 2009 Financial Results 4Cynosure Reports Third Quarter 2009 Financial Results 5Cynosure Reports Third Quarter 2009 Financial Results 6Cynosure Reports Third Quarter 2009 Financial Results 7Cynosure Reports Third Quarter 2009 Financial Results 8Cynosure Reports Third Quarter 2009 Financial Results 9Cynosure Reports Third Quarter 2009 Financial Results 10Cynosure Reports Third Quarter 2009 Financial Results 11Cynosure Reports Third Quarter 2009 Financial Results 12
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... chase down speeding vehicles as the movie Jurassic Park would ... certainly no slouch, research out today suggests. The University ... running speeds of five meat-eating dinosaurs that varied in size ... study believed to be the most accurate ever produced ...
... BOSTON Ever since the Manhattan project in ... nuclear science and technology. Yet,scientists still seek the ... of actinide compounds and materials using first principle ... to achievement. PNNL scientist Jun Li will ...
... 2007) Genetic testing can be used to help ... according to research published in the September 1, 2007, ... American Society of Hematology. This result represents one of ... to guide personal medical care. Because individuals metabolize ...
Cached Biology News:T. rex quicker than Becks, say scientists 2Genetics determine optimal drug dose of common anticoagulant 2
... the translation boosting Cap 1 structure. mScript™ ... 40% to 80% capped using co-transcriptional systems) ... mScript™ also features the Cap 1 structure, ... to 50% more efficient in in vivo ...
...
Request Info...
... pPIC9K and pPIC3.5K vectors carry the kanamycin ... Reagent in Pichia. Spontaneous generation of multiple ... to increased levels of Geneticin Reagent. Pichia ... screened for their level of resistance to ...
Biology Products: